Table 2.
Demographic and Clinical Features of 47 Patients Identified Through the Systematic Review Together With Those From the French Cohort
| Total cohort (n = 47) | |
| Median age (range) | 65 (41–90) |
| Men (n, %) | 30/46 (65) |
| Median PNS-Care Score (range) | 7 (1–10) |
| Tumor diagnosed before PNS (n, %) | 18/46 (39) |
| Tumor status at PNS diagnosis (n, %) | |
| Local tumor | 2/43 (4) |
| Lymph node, primary unknown | 26/43 (60) |
| Lymph node, primary known | 11/43 (25) |
| Distant metastasis | 4/43 (9) |
| Paraneoplastic neurologic syndromes (n, %) | |
| LEMS | 14/47 (29) |
| RPCS | 11/47 (23) |
| EM | 8/47 (17) |
| Other NM disordersa | 8/47 (17) |
| Other CNS disordersb | 6/47 (12) |
| Neural antibodies (n, %) | 38/45 (84) |
| High-risk Abs | 10/45 (22) |
| Intermediate-risk Abs | 15/45 (33) |
| Low-risk Abs (n, %) | 2/45 (4) |
| NF Abs | 8/45 (17) |
| Immunotherapy (n, %) | |
| Steroids | 23/39 (58) |
| IVIG | 21/39 (53) |
| PLEX | 4/39 (10) |
| Rituximab | 3/39 (7) |
| Other immunotherapiesc | 7/39 (17) |
| Outcomes (n, %) | |
| Recovery | 8/43 (18) |
| Partial recovery | 14/43 (32) |
| No improvement or progression | 6/43 (13) |
| Death | 15/43 (34) |
Abbreviations: Abs = antibodies; EM = encephalomyelitis; IVIG = IV immunoglobulins; NF = neurofilament; NM = neuromuscular; PLEX = plasma exchange; PNS = paraneoplastic neurologic syndrome; RPCS = rapidly progressive cerebellar syndrome.
Other NM disorders including sensory neuronopathy (2), motor neuron disorder (1), necrotizing myopathy (1), autonomic neuronopathy (1), dermatomyositis (1), sensory-motor axonal neuropathy (1), and myositis (1).
Other CNS disorders including brainstem encephalitis (3), limbic encephalitis (1), extralimbic encephalitis (1), and myelitis (1).
Other immunotherapies including cyclophosphamide (5), mycophenolate mofetil (1), and cyclosporine (1).